Polaryx Therapeutics, Inc. Common Stock
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $103.2M
- Price
- $2.07
- % Change (Daily % change from the live per-ticker quote feed.)
- -3.27%
- Volume
- 108.5K
About
Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL. PLX-200, a repurposed compound already utilized to address various diseases in both adult and pediatric populations. And PLX-300, derived from an edible plant, which works by activating PPARa to enhance the production of transcription factor EB. The company, established in 2014, maintains its base of operations in Paramus, New Jersey.
Quick stats
Shares outstanding49.8M
Computed float15.0M
Float / shares30.1%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0002075320
Websitehttps://polaryx.com
AI Summary
AI-generated1/15
standardneutraloffering
Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial
Polaryx Therapeutics closed a $10 million private placement (PIPE) financing, issuing approximately 2.5 million shares at an average price of $4.00.
The company intends to use the proceeds to fund the Phase 2 SOTERIA basket trial for its lead candidate PLX-200, which targets four lysosomal storage disorders.
Management stated the capital extends the operating runway through the second quarter of 2027, supporting the planned trial launch in the second half of 2026.